<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2811222945
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bonlevo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Intravenous infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AL RAZI PHARMA INDUSTRIES FACTORY LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES FACTORY LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2312]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is <strong>BONLEVO</strong>&nbsp; 500. <strong>BONLEVO</strong> &nbsp;500 contains a medicine called levofloxacin. This belongs to a group of medicines called antibiotics. Levofloxacin is a &lsquo;quinolone&rsquo; antibiotic. It works by killing the bacteria that cause infections in your body.</p><p><strong>BONLEVO 500 can be used to treat infections of the:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lungs, in people with pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract, including your kidneys or bladder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prostate gland, where you have a long lasting infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;</p><p>In some special situations, <strong>BONLEVO</strong> &nbsp;500<strong> </strong>may be used to lessen the chances of getting a pulmonary disease named anthrax or worsening of the disease after you are exposed to the bacteria causing anthrax.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not have this medicine and tell your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciprofloxacin or ofloxacin or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a problem with your tendons such as tendonitis that was related to treatment with a &lsquo;quinolone antibiotic&#39;. A tendon is the cord that joins your muscle to your skeleton.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are a child or a growing teenager</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant, might become pregnant or think you may be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are breast-feeding.</p><p>Do not have this medicine if any of the above applies to you. If you are not sure, talk to your doctor, nurse or pharmacist before you are given <strong>BONLEVO</strong> 500.</p><p><strong>Warning and Precautions</strong></p><p><strong>Talk to your doctor, nurse or pharmacist before you have your medicine if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are 60 years of age or older</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are using corticosteroids, sometimes called steroids (see section &ldquo;Other medicines and <strong>BONLEVO</strong> 500.&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a fit (seizure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had damage to your brain due to a stroke or other brain injury</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. You are more likely to have serious problems with your blood when taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had mental health problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had heart problems: caution should be taken when using this kind of medicine, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;),have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section &ldquo;Other medicines and <strong>BONLEVO</strong> &rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are diabetic</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have myasthenia gravis</p><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before being given <strong>BONLEVO</strong> 500.</p><p><strong>Other medicines and BONLEVO 500</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other</p><p>medicines. This is because <strong>BONLEVO</strong> 500 can affect the way some other medicines work. Also some medicines can affect the way <strong>BONLEVO</strong> 500 works.</p><p><strong>In particular, tell your doctor if you are taking any of the following medicines. This is because it can increase the chance of you getting side effects, when taken with BONLEVO 500:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids, sometimes called steroids &ndash; used for inflammation. You may be more likely to have inflammation and/or rupture of your tendons.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin - used to thin the blood. You may be more likely to have a bleed. Your doctor may need to take regular blood tests to check how well your blood can clot.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Theophylline - used for breathing problems. You are more likely to have a fit (seizure) if taken with <strong>BONLEVO</strong>&nbsp;500.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDS) - used for pain and inflammation such as aspirin, ibuprofen, fenbufen, ketoprofen, indomethacin. You are more likely to have a fit (seizure) if taken with <strong>BONLEVO</strong> 500.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin - used after organ transplants. You may be more likely to get the side effects of Ciclosporin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines known to affect the way your heart beats. This includes medicines used for</p><p>abnormal heart rhythm (antiarrhythmics such as quinidine, hydroquinidine, disopyramide, sotalol, dofetilide, ibutilide and amiodarone), for depression (tricyclic antidepressants such as amitriptyline and imipramine,), for psychiatric disorders (antipsychotics), and for bacterial infections (&lsquo;macrolide&rsquo; antibiotics such as erythromucin, azithromycin and clarithromycin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid &ndash; used for gout. Your doctor may want to use a lower dose, if you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine &ndash; used for ulcers and heartburn. Your doctor may want to use a lower dose, if you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if any of the above applies to you.</p><p><strong>Urine tests for opiates</strong></p><p>Urine tests may show &lsquo;false-positive&rsquo; results for strong painkillers called &lsquo;opiates&rsquo; in people having <strong>BONLEVO</strong> 500. If your doctor has prescribed a urine test, tell your doctor you are having <strong>BONLEVO</strong> 500.</p><p><strong>Tuberculosis tests</strong></p><p>This medicine may cause &ldquo;false negative&rdquo; results for some laboratory tests that search for the bacteria that cause tuberculosis.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not have this medicine if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant, might become pregnant or think you may be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are breast-feeding or planning to breast-feed</p><p><strong>Driving and using machines</strong></p><p>You may get side effects after being given this medicine, including feeling dizzy, sleepy, a spinning feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being able to concentrate and your reaction speed. If this happens, do not drive or carry out any work that requires a high level of attention.</p><p><strong>BONLEVO 500 contains sodium</strong></p><p>This medicine contains 181mg of sodium per 250 mg dose. This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>BONLEVO</strong>&nbsp;solution for infusion is a medicine for use in hospitals</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It will be given to you by a doctor or nurse as an injection. The injection will be into one of your veins and be given over a period of time (this is called an intravenous infusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For 500 mg <strong>BONLEVO</strong> 500, the infusion time should be 60 minutes or more</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your heart rate and blood pressure should be closely monitored. This is because an unusual fast beating of the heart and a temporary lowering of blood pressure are possible side effects that have been seen during the infusion of a similar antibiotic. If your blood pressure drops noticeably while you are being given the infusion, it will be stopped straight away</p><p><strong>How much BONLEVO 500 is given</strong></p><p>If you are not sure why you are being given <strong>BONLEVO</strong> 500<strong> </strong>or have any questions about how much <strong>BONLEVO</strong>&nbsp;500<strong> </strong>is being given to you, speak to your doctor, nurse or pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide on how much <strong>BONLEVO</strong> &nbsp;500<strong> </strong>you should have</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose will depend on the type of infection you have and where the infection is in your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The length of your treatment will depend on how serious your infection is</p><p><strong>Adults and the elderly</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia: 500 mg once or twice each day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of urinary tract, including your kidneys or bladder: 500 mg once each day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prostate gland infection: 500 mg once each day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of skin and underneath the skin, including muscles: 500 mg once or twice each day</p><p><strong>Adults and the elderly with kidney problems</strong></p><p>Your doctor may need to give you a lower dose.</p><p><strong>Children and Teenagers</strong></p><p>This medicine must not be given to children or teenagers.</p><p><strong>Protect your skin from sunlight</strong></p><p>Keep out of direct sunlight while having this medicine and for 2 days after you stop having it. This is because your skin will become much more sensitive to the sun and may burn, tingle or severely blister if you do not take the following precautions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you use high factor sun cream</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always wear a hat and clothes which cover your arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid sun beds</p><p><strong>If you have more BONLEVO <sup>&nbsp;</sup>500 than you should</strong></p><p>It is unlikely that your doctor or nurse will give you too much medicine. Your doctor and nurse will monitor your progress, and check the medicine you are given. Always ask if you are not sure why you are getting a dose of medicine. Having too much <strong>BONLEVO</strong> &nbsp;500<strong> </strong>may cause the following effects to happen: convulsive fits (seizures), feeling confused, dizzy, less conscious, having tremor and heart problems - leading to uneven heart beats as well as feeling sick (nausea).</p><p><strong>If you miss a dose of BONLEVO &nbsp;500 </strong></p><p>Your doctor or nurse will have instructions on when to give you this medicine. It is unlikely that you will not be given the medicine as it has been prescribed. However, if you do think you have missed a dose, tell your doctor or nurse.</p><p><strong>If you stop having BONLEVO &nbsp;500</strong></p><p>Your doctor or nurse will continue giving you <strong>BONLEVO</strong> &nbsp;500, even if you feel better. If it is stopped too soon, the infection may return, your condition may get worse or the bacteria may become resistant to the medicine. After a few days treatment with the solution for infusion, your doctor may decide to switch you to the tablet form of this medicine to complete your course of treatment. If you have any further questions on the use of this medicine, ask your doctor, nurse, or pharmacist.</p><p><strong>BONLEVO &nbsp;500 Mixture with other solutions for infusion: </strong></p><p><strong>BONLEVO</strong> &nbsp;500 is compatible with the following solutions for infusion:</p><p>0.9% sodium chloride solution.</p><p>5% glucose injection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild or moderate and often disappear after a short time.</p><p><strong>Stop having BONLEVO &nbsp;500 and tell a doctor or nurse straight away if you notice the following side effect:</strong></p><p><strong>Very rare (may affect up to 1 in 10 000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have an allergic reaction. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat, or tongue.</p><p><strong>Stop having BONLEVO &nbsp;500 and tell a doctor or nurse straight away if you notice any of the following</strong></p><p><strong>serious side effects - you may need urgent medical treatment:</strong></p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Watery diarrhoea which may have blood in it, possibly with stomach cramps and a high temperature. These could be signs of a severe bowel problem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and inflammation in your tendons or ligaments which could lead to rupture. The Achilles tendon is affected most often Fits (convulsions)</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Burning, tingling, pain or numbness. These may be signs of something called &lsquo;neuropathy&rsquo;.</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin rashes which may include blistering or peeling of the skin around your lips, eyes, mouth, nose and genitals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, skin and eyes becoming yellow in colour, dark-coloured urine, itching, or tender stomach (abdomen). These may be signs of liver problems which may include a fatal failure of the liver.</p><p>If your eyesight becomes impaired or if you have any other eye disturbances whilst having <strong>BONLEVO &nbsp;500</strong>, consult an eye specialist immediately.</p><p><strong>Tell your doctor if any of the following side effects gets serious or lasts longer than a few days:</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleeping problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea, vomiting) and diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the level of some liver enzymes in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions at the site of infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of a vein</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the number of other bacteria or fungi, infection by fungi named Candida, which may need to be treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the number of white blood cells shown up in the results of some blood tests (leukopenia, eosinophilia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling stressed (anxiety), feeling confused, feeling nervous, feeling sleepy, trembling, a spinning feeling (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way things taste, loss of appetite, stomach upset or indigestion (dyspepsia), pain in your stomach area, feeling bloated (flatulence) or constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching and skin rash, severe itching or hives (urticaria), sweating too much (hyperhidrosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain or muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show unusual results due to liver (bilirubin increased) or kidney (creatinine increased) problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General weakness</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising and bleeding easily due to a lowering in the number of blood platelets (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of white blood cells (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exaggerated immune response (hypersensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lowering of your blood sugar levels (hypoglycaemia). This is important for people that have diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seeing or hearing things that are not there (hallucinations, paranoia), change in your opinion and thoughts (psychotic reactions) with a risk of having suicidal thoughts or actions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling depressed, mental problems, feeling restless (agitation), abnormal dreams or nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingly feeling in your hands and feet (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your hearing (tinnitus) or eyesight (blurred vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual fast beating of your heart (tachycardia) or low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness. This is important in people with myasthenia gravis (a rare disease of the nervous system).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way your kidney works and occasional kidney failure which may be due to an allergic kidney reaction called interstitial nephritis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lowering in red blood cells (anemia): this can make the skin pale or yellow due to damage of the red blood cells; lowering in the number of all types of blood cells (pancytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, sore throat and a general feeling of being unwell that does not go away. This may be due to a lowering in the number of white blood cells (agranulocytosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of circulation (anaphylactic like shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of your blood sugar levels (hyperglycaemia) or lowering of your blood sugar levels leading to coma (hypoglycaemic coma). This is important for people that have diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way things smell, loss of smell or taste (parosmia, anosmia, ageusia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems moving and walking (dyskinesia, extrapyramidal disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary loss of consciousness or posture (syncope)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary loss of vision, inflammation of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment or loss of hearing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal fast heart rhythm, life-threatening irregular heart rhythm including cardiac arrest, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing or wheezing (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic lung reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sensitivity of your skin to sun and ultraviolet light (photosensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vessels that carry blood around your body due to an allergic reaction (vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tissue inside the mouth (stomatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle rupture and muscle destruction (rhabdomyolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint redness and swelling (arthritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain, including pain in the back, chest and extremities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attacks of porphyria in people who already have porphyria (a very rare metabolic disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Persistent headache with or without blurred vision (benign intracranial hypertension)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Keep the bottle in the outer carton in order to protect from light. No protection from light is required during the infusion.</p><p>Once the infusion bottle has been opened (rubber stopper perforated) the solution should be used immediately (within 3 hours) in order to prevent any bacterial contamination.</p><p>Do not use this medicine if you notice that the solution is not clear, greenish-yellow solution and/or has particles in it.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>The active substance is Levofloxacin. </u></p><p>One ml contains 5 mg Levofloxacin.</p><p>Each 100 ml bottle contains 500 mg Levofloxacin.</p><p><u>The other ingredients are:</u></p><p>Sodium chloride, hydrochloric acid, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BONLEVO  500 is a clear solution, greenish-yellow, without particles
Perception may vary. BONLEVO  500 is supplied in plastic bottles of 100 ml.
Pack sizes: 1 bottle, 100 mL LDPE bottle.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alrazi Pharmaceutical Industries Factory Co.,</p><p>2<sup>nd</sup> Industrial City, Street no. 67, Cross 110, P.O. Box 3992,</p><p>Dammam, Kingdom of Saudi Arabia</p><p>Tel: +966 13 8281919</p><p>Fax: +966 13 8251313</p><p>Website: www.alrazi-pharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم هذا&nbsp;الدواء بونـليفو 500 يحتوي على مادة فعالة تُسمّى ليفوفلوكساسين تنتمي إلى مجموعة الأدوية التي تُسمّى مضادات حيوية وتنتمي بشكل خاص إلى عائلة الكينولونات وتعمل عن طريق قتل البكتيريا التي تسبّب بعض حالات الخمج والالتهابات في جسمك.</p><p dir="RTL"><strong>يسمح بونـليفو 500</strong><strong><sup>&nbsp; </sup></strong><strong>بعلاج حالات الالتهابات التي تصيب:</strong></p><p dir="RTL">&bull; الرئتين لدى الأشخاص المصابين بذات الرئة</p><p dir="RTL">&bull; المسالك البولية بما فيها&nbsp;الكلى أو المثانة</p><p dir="RTL">&bull; البروستات عندما تكون مصابا بحالة خمج طويلة الأمد</p><p dir="RTL">&bull; الجلد والأنسجة تحت الجلد بما في ذلك العضلات (&quot;الأنسجة اللينة&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل هذا الدواء وأخبر طبيبك إذا:</strong></p><p dir="RTL">&middot;&nbsp; &nbsp;كنت تعاني من حساسية من الليفوفلوكساسين أو مضاد حيويّ آخر من فئة الكينولون مثل موكسيفلوكساسين أو سيبروفلوكساسين أو أوفلوكساسين أو أيّ مكوّنات أخرى في هذا الدواء كما هي مذكورة في القسم 6 أدناه.</p><p dir="RTL">&middot;&nbsp; عانيت من أعراض الحساسية وهي ما يلي: طفح جلدي، صعوبات في البلع أو التنفّس، تورّم الشفتين أو الوجه أو الحلق أو اللسان.</p><p dir="RTL">&middot;&nbsp; &nbsp;كنت تعاني من الصرع أو إذا أصبت بنوبات صرع في الماضي.</p><p dir="RTL">&middot;&nbsp; عانيت يوما من مشكلة في الأوتار مثل التهاب الوتر الناتج عن علاج بمضاد حيويّ من فئة الكينولون. الأوتار هي الحبال الليفية التي تصل العضلات بالهيكل العظمي.</p><p dir="RTL">&middot;&nbsp; كنت طفلا أو مراهقا في طور النموّ</p><p dir="RTL">&middot;&nbsp; كنتِ حاملا أو تعتقدين نفسكِ حاملا أًو قد تصبحين حاملا.ً</p><p dir="RTL">&middot;&nbsp; كنتِ مرضعة.</p><p dir="RTL">لا تأخذ هذا الدواء إذا كنت تعاني من إحدى الحالات المذكورة أعلاه. إذا لم تكن واثقا،ً استشر الطبيب أو الصيدلي أو الممرّض/الممرّضة قبل أن تتلقّى بونـليفو<sup>&reg;</sup> 500 .</p><p dir="RTL"><strong>تحذيرات واحتياطات:</strong></p><p dir="RTL"><strong>يجب عليك التوجّه إلى الطبيب أو الممرّض/الممرّضة أو الصيدلي قبل استعمال هذا الدواء في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp; إذا كنت في ال 60 من العمر أو أكثر.</p><p dir="RTL">&middot;&nbsp; إذا كنت تأخذ ستيرويدات وتُسمّى أحيانا ستيرويدات قشرية (راجع فقرة &quot; تفاعلات بونـليفو500<strong> </strong>مع الادوية الأخرى أدناه).</p><p dir="RTL">&middot;&nbsp; إذا أصُبت يوما بنوبات.</p><p dir="RTL">&middot;&nbsp; إذا تعرّض دماغك للضرر بسبب سكتة دماغية&nbsp;أو إصابة أخرى في الدماغ.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من مشاكل كلوية.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من &quot;نقص في نازعة هيدروجين غلوكوز- 6- فوسفات&quot; ، ففي هذه الحالة يزداد خطر الإصابة بمشاكل خطيرة في الدم إذا كنت تأخذ هذا الدواء.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني أو عانيت يوما من مشاكل في الصحّة العقلية.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني أو عانيت يوما من اضطرابات قلبية. خذ هذا الدواء بحذر: - إذا كنت تعاني دائمًا من إطالة في كيو تي (تظهر على مخطط القلب الكهربائي، أيّ تسجيل نشاط القلب الكهربائي) أو عدم استقرار في أملاح الدم (خاصة تركيز ضعيف للبوتاسيوم والمغنيزيوم في الدم )، إذا كان معدّل ضربات القلب لديك بطيئًا جدًا (بطء القلب)، - إذا كنت تعاني من قصور في القلب (فشل القلب) ، إذا أصبت باحتشاء عضلي قلبي (احتشاء عضلة القلب)، إذا كن/تِ امرأة أو شخصًا متقدّمًا في السنّ، إذا كنت تأخذ أدوية أخرى يمكن أن تؤدّي إلى تغييرات ليست طبيعية في مخطط كهربائية القلب (راجع فقرة &quot; تفاعلات بونـليفو500<strong><sup>&reg;</sup></strong> مع الادوية الأخرى &quot; أدناه).</p><p dir="RTL">&middot;&nbsp; إذا كنت مصاب بداء السكّري.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني أو عانيت يوما من مشاكل في الكبد.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من الوهن العضلي الوبيل (ضعف عضلي حادّ).</p><p dir="RTL">إذا لم تكن متأكّدا مما إذا كانت تنطبق عليك إحدى الحالات أعلاه، استشر الطبيب أو الصيدلي أو الممرّض/ة قبل أن تتلقّى بونـليفو<sup>&reg;</sup> 500.</p><p dir="RTL"><strong>تفاعلات بونـليفو&nbsp;</strong><strong>500</strong><strong>&nbsp;مع الادوية الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء أن تُعلم الطبيب أو الصيدلي إذا كنت تتناول حاليا أو تناولت مؤخّرا أو تنوي تناول أيّ أدوية أخرى، لأنّ بونـليفو 500 يمكن أن يؤثّر على كيفية عمل بعض الأدوية الأخرى كما أنّ بعض الأدوية يمكن أن تؤثّر على كيفية عمل بونـليفو 500.</p><p dir="RTL"><strong>بشكل خاص، أعلم طبيبك إذا كنت تتناول أحد الأدوية التالية لأنّ ذلك قد يزيد من خطر تعرّضك للتأثيرات الجانبية عند تناولها في فترة العلاج مع بونـليفو&nbsp;</strong><strong>500</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp; الاستيرويدات التي تُسمّى أحيانا بالستيرويدات القشرية وتُستعمل لعلاج الالتهاب. فقد يزيد خطر تعرّضك للالتهبات أو تمزق الأوتار.</p><p dir="RTL">&middot;&nbsp; الوارفارين المستعمل لسيولة الدم. فقد يزيد خطر تعرّضك لنزيف، قد يحتاج طبيبك إلى إجراء فحوصات الدم&nbsp;لك بانتظام للتحقّق من قدرة دمك على التخثّر.</p><p dir="RTL">&middot;&nbsp; الثيوفيلين المستعمل في أمراض التنفّس المزمنة. فقد يزيد خطر تعرّضك (لنوبات) إذا تناولتها مع بونـليفو 500.</p><p dir="RTL">&middot;&nbsp; مضادات الالتهاب غير الستيرويدية التي تُستعمل للألم والالتهاب مثل الأسبيرين والإيبروفين والفنبوفين والكيتوبروفين والإندوميثاسين. فقد يزيد خطر تعرّضك (لنوبات) إذا تناولتها مع بونـليفو 500.</p><p dir="RTL">&middot;&nbsp; السيكلوسبورين المستعمل بعد زرع الأعضاء، فقد يزيد خطر تعرّضك للتأثيرات الجانبية للسيكلوسبورين.</p><p dir="RTL">&middot;&nbsp; الأدوية التي يعرف عنها أنها تؤثّر على دقّات القلب أيّ الأدوية المستعملة لاضطرابات النظم القلبي (المضادات المستخدمة لاضطراب نبضات القلب مثل الكينيدين والهيدروكينيدين والديزوبيراميد والأميودارون والسولاتول والدوفيتيليد والإيبوتوليد) وللإكتئاب (مضادات الاكتئاب الثلاثية الحلقات مثل الأميتريبتيلين أو الإيميبرامين) وللأمراض العقلية (بعض المؤثّرات العقلية) ولحالات الخمج البكتيرية (المضادات الحيوية من فئة الماكروليد مثل الإيريثروميسين والأزيثروميسين والكلاريثروميسين).</p><p dir="RTL">&middot;&nbsp; البروبينيسيد المستعمل لعلاج النقرس قد يخفّض طبيبك الجرعة إذا ضعفت وظيفتك الكلوية.</p><p dir="RTL">&middot;&nbsp; السيميتيدين المستعمل للقرحة وحرقة المعدة قد يخفّض طبيبك الجرعة إذا ضعفت وظيفتك الكلوية.</p><p dir="RTL">إذا كانت إحدى الحالات أعلاه تنطبق عليك، استشر الطبيب.</p><p dir="RTL"><strong>إختبار البول للمواد الأفيونية:</strong></p><p dir="RTL">قد تظهر اختبارات البول نتائج &quot;إيجابية كاذبة&quot; لمسكنات الألم القوية المسماة &quot;الأفيون&quot; لدى الأشخاص الذين يتناولون بونـليفو 500 إذا وصف طبيبك اختبار البول، أخبره بأنك تتناول بونـليفو 500.</p><p dir="RTL"><strong>الكشف عن السل:</strong></p><p dir="RTL">في بعض فحوصات الكشف عن السلّ، قد يعطي هذا الدواء نتائج سلبية خاطئة.</p><p dir="RTL"><strong>الحمل والإرضاع:</strong></p><p dir="RTL">لا ينبغي بك تلقّي هذا الدواء في الحالات التالية:</p><p dir="RTL">&middot;&nbsp; &nbsp;إذا كنتِ حاملا أو تعتقدين نفسك حاملا أًو يمكن أن تحملي.</p><p dir="RTL">&middot;&nbsp; &nbsp;إذا كنتِ مرضعة أو تنوين الإرضاع.</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآلات:</strong><br />يمكن أن يسبّب إعطاء هذا الدواء تأثيرات جانبية مثل البلادة والنعاس والدوار أو تغييرات في النظر. ويمكن أن يؤثّر بعض هذه التأثيرات الجانبية على قدرتك على التركيز وعلى سرعة ردّة الفعل لديك. في حال حصول هذا، لا تقد سيارة ولا تقم بأيّ عمل يتطلبّ مستوى عاليا من الانتباه.</p><p dir="RTL"><strong>يحتوي بونـليفو&nbsp;</strong><strong>500&nbsp;</strong><strong>على الصوديوم:</strong></p><p dir="RTL">يحتوي هذا الدواء على 181 ملغ من الصوديوم في كل 250 ملغ من المحلول يجب أخذ هذا المحتوى بعين الاعتبار لدى المرضى الذين يتبعون حمية منخفضة الملح.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp; بونـليفو 500 ، محلول للتسريب هو دواء يستعمل في المستشفيات.</p><p dir="RTL">&middot;&nbsp; سوف يعطيك إياه طبيب أو ممرّض/ة عن طريق الحقن سيجرى الحقن في أحد أوردتك وسيعطى لفترة من الوقت (يسمّى هذا تسريبًا داخل الوريد).</p><p dir="RTL">&middot;&nbsp; لإعطاء بونـليفو&nbsp;500 ، يجب أن يكون وقت التسريب 60 دقيقة على الأقلّ.</p><p dir="RTL">&middot;&nbsp; يجب مراقبة سرعة قلبك وضغط دمك مراقبة دقيقة لأنّ سرعة غير اعتيادية في دقّات القلب وانخفاضًا مؤقّتًا في ضغط الدم هما تأثيران جانبيان محتملان لوحظا في خلال تسريب مضاد حيويّ مماثل. فإذا انخفض ضغط دمك انخفاضًا ملحوظًا وأنت تتلقّى التسريب، سيتم إيقافه على الفور</p><p dir="RTL"><strong>ما هي كمية بونـليفو&nbsp;500 التي تُعطى:</strong></p><p dir="RTL">إذا لم تكن واثقًا من سبب إعطائك بونـليفو 500، أو إذا كان لديك أيّ سؤال حول كمية بونـليفو&nbsp;<strong><sup>&nbsp;</sup></strong>500 التي تُعطى لك، تحدّث إلى الطبيب أو الممرّض/ة أو الصيدلي.</p><p dir="RTL">&middot;&nbsp; سوف يقرّر طبيبك كمية بونـليفو<strong> </strong>500 الذي يجب عليك تلقّيها.</p><p dir="RTL">&middot;&nbsp; سوف تتوقّف الجرعة على نوع الالتهاب الذي تعاني منه و على موقعه في جسمك.</p><p dir="RTL">&middot;&nbsp; سوف تتوقّف مدّة علاجك على مدى خطورة الالتهاب الذي تعاني منه.</p><p dir="RTL"><strong>البالغون والمسنّون:</strong></p><p dir="RTL">&middot;&nbsp; ذات الرئة: 500 ملغ مرّة أو مرّتان في اليوم.</p><p dir="RTL">&middot;&nbsp; التهاب المسالك البولية بما في ذلك الكليتان أو المثانة: 500 ملغ مرّة في اليوم.</p><p dir="RTL">&middot;&nbsp; التهاب البروستات: 500 ملغ مرّة في اليوم</p><p dir="RTL">&middot;&nbsp; التهاب الجلد والأنسجة تحت الجلد بما في ذلك العضلات: 500 ملغ مرة أو مرّتان في اليوم</p><p dir="RTL"><strong>البالغون والمسنّون الذين يعانون من مشاكل كلوية:</strong></p><p dir="RTL">قد يضطر طبيبك إلى إعطائك جرعة أدنى.</p><p dir="RTL"><strong>الأطفال والمراهقون:</strong></p><p dir="RTL">لا ينبغي إعطاء هذا الدواء للأطفال والمراهقين.</p><p dir="RTL"><strong>احمِ بشرتك من أشعّة الشمس:</strong></p><p dir="RTL">لا تتعرّض لأشعّة الشمس المباشرة خلال فترة العلاج وخلال اليومين التاليين، ففي خلال العلاج تصبح بشرتك أكثر حساسية بكثير تجاه الشمس وقد تحترق أو تشعر بوخز خفيف أو تمتلئ بشرتك ببثور كثيرة إذا لم تتّخذ الاحتياطات التالية:</p><p dir="RTL">&middot;&nbsp; استعمل مرهم وقاية قويا من أشعّة الشمس.</p><p dir="RTL">&middot;&nbsp; اعتمر دائما قبّعة وارتدِ ثيابا تغطّي ذراعيك وساقيك.</p><p dir="RTL">&middot;&nbsp; &nbsp;تفادَ التعرّض للأشعة فوق البنفسجية الاصطناعية في حجرة التسمير.</p><p dir="RTL"><strong>إذا تلقّيت كمية من بونـليفو 500 أكثر من التي عليك تلقّيها:</strong></p><p dir="RTL">من غير المحتمل أن يعطيك طبيبك أو ممرّضك/ممرّضتك كمية كبيرة من هذا الدواء. سوف يراقبان تقدّم حالتك الصحية ويتحققان من الدواء الذي يعطى لك. إسأل دائمًا إذا لم تكن واثقًا من السبب الذي تتلقّى لأجله جرعة من هذا الدواء. قد يسبّب تلقّي جرعة مفرطة من بونـليفو<strong><sup>&reg;</sup></strong>500 التأثيرات التالية: نوبات اختلاج، شعور باختلاط ذهنيّ وبدوار وبنقص في الوعي ورجفة ومشاكل في القلب تؤدّي إلى عدم انتظام دقّات القلب وإلى شعور بالغثيان.</p><p dir="RTL"><strong>في حال نسيان جرعة من بونـليفو&nbsp;</strong><strong>500:</strong></p><p dir="RTL">سيكون طبيبك أو ممرضّك/ممرّضتك مزوّدَين بتعليمات حول الوقت الذي يجب إعطاؤك فيه هذا الدواء. وبالتالي من غير المحتمل ألا يعطى هذا الدواء وفقًا للوصفة الطبية. ومع ذلك إذا اعتقدت أنه تمّ نسيان جرعة، أعلم طبيبك أو ممرّضك/ممرّضتك.</p><p dir="RTL"><strong>إذا أوقفت علاج بونـليفو&nbsp;500:</strong></p><p dir="RTL">سوف يواصل طبيبك أو ممرّضك/ممرّضتك إعطاءك بونـليفو<sup>&reg;</sup> 500<strong><sup> </sup></strong>حتّى ولو شعرت بتحسّن. فإذا تمّ إيقاف الدواء باكرًا، يمكن أن يعاودك الخمج أو قد تسوء حالتك أو قد تصبح البكتيريا مقاومة للدواء. بعد أيام قليلة من العلاج بمحلول التسريب، قد يقرّر طبيبك نقلك إلى الأقراص من هذا الدواء لإكمال مدّة علاجك. إذا كان لديك أسئلة أخرى حول استعمال هذا الدواء، إطرحها على الطبيب أو الصيدلي.</p><p dir="RTL"><strong>خلط بونـليفو 500 مع المحاليل الأخرى للحقن: </strong></p><p dir="RTL">بونـليفو 500 متوافق مع المحاليل التالية</p><p dir="RTL">0.9% محلول كلوريد الصوديوم</p><p dir="RTL">5% الجلكوز</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إذا لاحظت التأثيرات الجانبية التالية، يجب إيقاف إعطاء بونـليفو<sup>&nbsp;</sup>500</strong><strong><sup> </sup></strong><strong>ويجب عليك أن تُعلم الطبيب أو الممرّض/ة على الفور:</strong></p><p dir="RTL"><strong>تأثيرات نادرة جدا (تصيب أقلّ من شخص واحد من أصل 10000)</strong></p><p dir="RTL">&nbsp;وجود تفاعلات تحسسية والاعراض ممكن أن تكون طفح جلدي، صعوبات في البلع أو التنفّس، تورّم الشفتين أو الوجه أو الحلق أو اللسان.</p><p dir="RTL"><strong>إذا لاحظت أيا من التأثيرات الجانبية الخطيرة التالية،يجب إيقاف إعطاء بونـليفو&nbsp;</strong><strong>&nbsp;500&nbsp;</strong><strong>ويجب عليك أن تُعلم الطبيب أو الممرّض/ة على الفور - قد تحتاج إلى علاج طبيّ طارئ:</strong></p><p dir="RTL"><strong>تأثيرات نادرة (تُصيب أقلّ من شخص واحد من أصل 1000)</strong></p><p dir="RTL">&middot;&nbsp; إسهال حاد يمكن أن يحتوي على دماء وقد يترافق مع مغص معديّ وحرارة مرتفعة. قد تكون هذه العوارض عوارض مرض خطير في الأمعاء.</p><p dir="RTL">&middot;&nbsp; ألم والتهاب في الأوتار أو الأربطة مع إمكانية التمزّق غالبا ما يصاب وتر العرقوب نوبات اختلاج.</p><p dir="RTL"><strong>تأثيرات نادرة جدا (تُصيب أقلّ من شخص واحد من أصل 10000)</strong></p><p dir="RTL">شعور بالحرق أو الوخز أو الألم أو الخدر قد تكون هذه العوارض عوارض مرض يسمّى &quot;الاعتلال العصبي&quot;.</p><p dir="RTL"><strong>تأثيرات غير محددة (لا يمكن تحديد معدّل حصولها استنادًا إلى المعطيات المتوافرة):</strong></p><p dir="RTL">&middot;&nbsp; طفح جلديّ حاد قد يتضمّن تبثّر الجلد أو تقشّره حول الشفتين والعينين والفم والأنف والأعضاء التناسلية.</p><p dir="RTL">&middot;&nbsp; فقدان الشهية، اصفرار الجلد والعينين، بول داكن اللون، حكّة أو الشعور بألم عند لمس البطن. قد تكون هذه الإشارات عوارض مرض في الكبد يمكن أن يتطوّر ليصبح قصورًا كبديا قد يؤدّي إلى الوفاة.</p><p dir="RTL">&middot;&nbsp; إذا عانيت من اضطرابات في النظر أو من مشكلة على مستوى العينين في خلال العلاج ب بونـليفو<sup>&reg;</sup> 500، استشر طبيب عيون على الفور أعلم طبيبك في حال تفاقم أحد التأثيرات التالية أو استمرّ لأكثر من بضعة أيام:</p><p dir="RTL"><strong>تأثيرات شائعة (تُصيب أقلّ من شخص واحد من أصل 10)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعّك (غثيان، تقيؤ) وإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدّل بعض مواد الكبد في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حساسية في موقع التسريب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وريد.</p><p dir="RTL"><strong>تأثيرات غير شائعة (تُصيب أقلّ من شخص واحد من أصل 100)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تكاثر بكتيريا أخرى أو فطريات، عدوى بنوع من الفطريات من نوع المبيضّات (قلاع) قد يتطلبّ علاجًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغيير عدد بعض كريات الدم البيضاء في الدم (نقص الكريات البيض، فرط الحمضات) يظهر في تحاليل الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضغط (قلق)، تشوّش ذهني، عصبية، نعاس، رجفة، إحساس بالدوار (دوار استداري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفّس (صعوبة التنفّس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغيير الذوق، فقدان الشهية، اضطرابات معدية أو صعوبة في الهضم (عسر هضم)، ألم في منطقة المعدة، انتفاخ أو إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حكّة مع طفح جلدي، حكّة قوية أو شرى، تعرّق مفرط (فرط التعرّق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع في المفاصل أو العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تحاليل دم تعطي نتائج غير اعتيادية تشير إلى مرض في الكبد (ارتفاع البيلوروبين) أو في الكلى (ارتفاع الكرياتينين). في المفاصل أو العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تعب عام.</p><p dir="RTL"><strong>تأثيرات نادرة (تُصيب أقلّ من شخص واحد من أصل 1000)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ميل إلى &quot;الازرقاق&quot; والنزف بسبب انخفاض عدد صفيحات الدم (قلةّ الصفيحات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد بعض كريات الدم البيض (قلةّ العدلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; استجابة مناعية مفرطة (حساسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات سكّر الدم (الغلوكوز) في الدم (نقص سكّر الدم). هذا مهمّ للأشخاص المصابين بالداء السكّري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير موجودة (هلوسات، جنون العظمة)، تغيير في رأيك وأفكارك (ارتكاسات ذُهانية) مع خطر أن تراودك أفكار أو أفعال إنتحارية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كآبة، اضطرابات عقلية، تهيج، أحلام غير اعتيادية، كوابيس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تنمّل في اليدين والقدمين (تشوّش الحسّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات سمعية (طنين) أو بصرية (عدم وضوح الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دقّات قلب أسرع من العادة (تسرّع القلب) أو انخفاض ضغط الدم (نقص ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عضلي وهذا مهمّ للغاية لدى المرضى المصابين بالوهن العضلي الوبيل (مرض نادر في الجهاز العصبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الوظيفة الكلوية مع فشل كلويّ أحيانًا، بعد ارتكاس تحسسي كلوي يسمّى التهاب الكلية الخلالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL"><strong>تأثيرات غير محددة (لا يمكن تحديد معدّل حصولها استنادًا إلى المعطيات المتوافرة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في كريات الدم الحمر (فقر دم) بسبب تضرّر كريات الدم الحمر. يمكن أن يسبّب هذا شحوب البشرة أو اصفرارها وانخفاض عدد كل أنواع كريات الدم (قلةّ الكريات الشاملة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمى، ألم في الحلق وشعور عام بالتوعّك المستمرّ، مما يمكن أن ينتج عن انخفاض عدد بعض كريات الدم البيض (ندرة المحببات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فشل الدورة الدموية (صدمة تأقية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدّل السكّر (غلوكوز) في الدم (فرط سكّر الدم) أو انخفاض هذا المعدّل (نقص سكّر الدم) مما يمكن أن يؤدّي إلى غيبوبة نقص سكّر الدم وهذا مهمّ جدًا لدى مرضى السكّري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في حاسّة الشمّ، فقدان حاسة الشمّ أو الذوق (ضلال الشمّ، فقد حاسّة الشمّ، فقد حاسّة الذوق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الحركات والسير (خلل الحركة، اضطرابات خارج الهرمية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فقدان عابر في الوعي وفي التوتّر الوضعي (إغماء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فقدان عابر للبصر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو فقدان السمع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تسارع غير طبيعي في النظم القلبي، عدم انتظام دقّات القلب يهدّد الحياة، بما في ذلك توقّف القلب وتغيير النظم القلبي (إطالة فارق كيو تي تظهر على مخطط كهربائية القلب أيّ على تسجيل نشاط القلب الكهربائي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفّس أو تنفّس مع صفير (تشنّج قصبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حساسية رئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية البشرة تجاه الشمس أو الأشعّة فوق البنفسجية الاصطناعية (تحسس ضوئي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الأوعية الدموية بسبب ارتكاس تحسسي (التهاب وعائي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء المخاطيّ في الفم (التهاب الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تمزّق وتدهور عضلي (إنحلال الربيدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;احمرار وتورّم المفاصل (التهاب المفاصل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم بخاصة على مستوى الظهر والصدر والأعضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوبات بورفيريا لدى المرضى الذين يعانون من هذا المرض (مرض أيضيّ نادر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صداع مستمرّ مع أو بدون عدم وضوح في الرؤية (فرط ضغط الدم الحميد داخل الجمجمة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة لا تزيد عن &deg;30م</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ القارورة في العلبة الخارجية لحمايتها من النور. ما من ضرورة للحماية من النور في خلال عملية التنقيط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عندما تُفتح قارورة الحقن (بعد ثقب السدادة المطّاطية)، يجب استعمال المحلول على الفور (في غضون 3 ساعات) لمنع أيّ تلوّث بكتيري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا العلاج إذا لاحظت أنّ المحلول غير صافٍ و/أو ليس لونه مخضرًّا أصفر و/أو إذا كان يحتوي على جُسيمات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>المادة الفاعلة هي الليفوفلوكساسين</u></p><p dir="RTL">واحد مل يحتوي على 5 ملغ من الليفوفلوكساسين</p><p dir="RTL">كل 100 مل عبوة تحتوي على 500 ملغ من الليفوفلوكساسين</p><p dir="RTL"><strong><u>المركّبات الأخرى هي</u></strong></p><p dir="RTL">كلوريد الصوديوم، هيدروكسيد الصوديوم، حامض الهيدروكلوريك وماء لمستحضرات الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بونـليفو 500، محلول للتسريب هو محلول صاف، لونه مخضرّ أصفر، لا يحتوي على جُسيمات يأتي في عبوة 100مل</p><p style="text-align:right">حجم العبوة : علبة واحدة, 100 مل علبة بولي إيثيلين منخفض الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مصنع شركة الرازي للصناعات الدوائية</p><p dir="RTL">الدمام &ndash; شارع رقم 67 تقاطع 110 &ndash; المدينة الصناعية الثانية</p><p dir="RTL">رقم المبنى 3992 &ndash; المملكة العربية السعودية</p><p dir="RTL">تلفون: +966 13 828 1919</p><p dir="RTL">فاكس: +966 13 828 1313</p><p dir="RTL">الموقع الإلكتروني: www.alrazi-pharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin solution for Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin: 500mg/100mL
Each ml contains 5 mg Levofloxacin
100 ml of solution for infusion contains 500 mg of levofloxacin as levofloxacin hemihydrate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
A clear and Yellow-Greenish solution.
pH: 3.8 – 5.8.
Osmolality ranging from 270 to 340mOsmol/kg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levofloxacin solution for infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):<br />Acute pyelonephritis and complicated urinary tract infections (see section 4.4)<br />&bull; Chronic bacterial prostatitis.<br />&bull; Inhalation Anthrax: post exposure prophylaxis and curative treatment (see section 4.4).<br />In the below mentioned indications levofloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.<br />&bull; Community-acquired pneumonia.<br />&bull; Complicated skin and soft tissue infections<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levofloxacin solution for infusion is administered by slow intravenous infusion once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen. Treatment with Levofloxacin after initial use of the intravenous preparation may be completed with an appropriate oral presentation according to the SPC for the film-coated tablets and as considered appropriate for the individual patient. Given the bioequivalence of the parenteral and oral forms, the same dosage can be used.</p><p><strong>Posology</strong></p><p>The following dose recommendations can be given for levofloxacin.</p><table border="1" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td colspan="2" style="vertical-align:top; width:619px"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top; width:268px"><p>Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min) <strong>Indication</strong></p></td><td colspan="3" style="vertical-align:top; width:177px"><p><strong>Daily dose regimen </strong>(according to severity)</p></td><td style="vertical-align:top; width:173px"><p><strong>Total duration of treatment</strong>(according to severity)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:268px"><p style="text-align:center">Community-acquired pneumonia</p></td><td colspan="3" style="vertical-align:top; width:177px"><p style="text-align:center">500 mg once or twice daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">7 - 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:268px"><p style="text-align:center">Acute Pyelonephritis</p></td><td colspan="3" style="vertical-align:top; width:177px"><p style="text-align:center">500 mg once daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">7 - 10 days</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:268px"><p style="text-align:center">Complicated urinary tract infections</p></td><td colspan="3" style="vertical-align:top; width:177px"><p style="text-align:center">500 mg once daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">7 - 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:268px"><p style="text-align:center">Chronic bacterial prostatitis</p></td><td colspan="3" style="vertical-align:top; width:177px"><p style="text-align:center">500 mg once daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">28 days</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:268px"><p style="text-align:center">Complicated skin and soft tissue infections</p></td><td colspan="3" style="vertical-align:top; width:177px"><p style="text-align:center">500 mg once or twice daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">7 - 14 days</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center">Inhalation anthrax</p></td><td colspan="2" style="vertical-align:top; width:178px"><p style="text-align:center">500 mg once daily</p></td><td style="vertical-align:top; width:173px"><p style="text-align:center">8 weeks</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Special populations</u></strong></p></td></tr><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0" style="width:468px"><tbody><tr><td colspan="4" style="vertical-align:top; width:464px"><p><strong><u>Impaired renal function (creatinine clearance&nbsp;&lt;50 ml/min)&nbsp;Dose regimen</u></strong></p></td></tr><tr><td style="vertical-align:top; width:145px">&nbsp;</td><td style="vertical-align:top; width:106px"><p><strong>250 mg/24h</strong></p></td><td style="vertical-align:top; width:110px"><p><strong>500 mg/24h</strong></p></td><td style="vertical-align:top; width:102px"><p><strong>500 mg/12 h</strong></p></td></tr><tr><td style="vertical-align:top; width:145px"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top; width:106px"><p><em>first dose:</em></p><p>250 mg</p></td><td style="vertical-align:top; width:110px"><p><em>first dose:</em></p><p>500 mg</p></td><td style="vertical-align:top; width:102px"><p><em>first dose:</em></p><p>500 mg</p></td></tr><tr><td style="vertical-align:top; width:145px"><p>50 - 20 ml/min</p></td><td style="vertical-align:top; width:106px"><p><em>then:</em></p><p>125 mg/24 h</p></td><td style="vertical-align:top; width:110px"><p><em>then:</em></p><p>250 mg/24 h</p></td><td style="vertical-align:top; width:102px"><p><em>then</em>:</p><p>250 mg/12 h</p></td></tr><tr><td style="vertical-align:top; width:145px"><p>19-10 ml/min</p></td><td style="vertical-align:top; width:106px"><p><em>then:</em></p><p>125 mg/48 h</p></td><td style="vertical-align:top; width:110px"><p><em>then:</em></p><p>125 mg/24 h</p></td><td style="vertical-align:top; width:102px"><p><em>then:</em></p><p>125 mg/12 h</p></td></tr><tr><td style="vertical-align:top; width:145px"><p>&lt;10 ml/min</p><p>(including haemodialysis and CAPD)&nbsp;</p></td><td style="vertical-align:top; width:106px"><p><em>then:</em></p><p>125 mg/48 h</p></td><td style="vertical-align:top; width:110px"><p><em>then:</em></p><p>125 mg/24 h</p></td><td style="vertical-align:top; width:102px"><p><em>then:</em></p><p>125 mg/24 h</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Impaired liver function</strong></p><p>No adjustment of dose is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Elderly population</strong></p><p>No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Paediatric population</strong></p><p>Levofloxacin is contraindicated in children and growing adolescents (see section 4.3).</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Method of administration</u></strong></p><p>Levofloxacin solution for infusion is only intended for slow intravenous infusion; it is administered once or twice daily. The infusion time must be at least 30 minutes for 250 mg or 60 minutes for 500 mg levofloxacin solution for infusion (see section 4.4).</p><p>For incompatibilities see section 6.2 and compatibility with other infusion solutions see section 6.6.</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, any other quinolone and to any of the excipients listed in section 6.1,
• Patients with epilepsy,
• Patients with history of tendon disorders related to fluoroquinolone administration,
• Children or growing adolescents (up to age of 18),
• During pregnancy, 
• Breast-feeding women


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>The use of levofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with levofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><u>Prolonged, disabling and potentially irreversible serious adverse drug reactions</u></p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. Levofloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).</p><p>Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.</p><p>Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><strong>Infusion Time</strong></p><p>The recommended infusion time of at least 30 minutes for 250 mg or 60 minutes for 500 mg Levofloxacin Solution for infusion should be observed. It is known for ofloxacin, that during infusion tachycardia and a temporary decrease in blood pressure may develop. In rare cases, as a consequence of a profound drop in blood pressure, circulatory collapse may occur. Should a conspicuous drop in blood pressure occur during infusion of levofloxacin, (l-isomer of ofloxacin) the infusion must be halted immediately.</p><p><strong>Sodium content</strong></p><p>This medicinal product contains 7.6 mmol (177 mg) sodium per 50 ml dose and 15.4 mmol (354 mg) per 100 ml dose. To be taken into consideration by patients on a controlled sodium diet.</p><p><strong>Tendinitis and tendon rupture</strong></p><p>Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment.</p><p>The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, patients receiving daily doses of 1000 mg, and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.</p><p style="text-indent:50px">At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with levofloxacin should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur.</p><p><strong>Clostridium difficile-associated disease</strong></p><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with Levofloxacin(including several weeks after treatment), may be symptomatic of&nbsp;Clostridium difficile-associated disease (CDAD), CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.</p><p><strong>Patients predisposed to seizures</strong></p><p>Quinolones may lower the seizure threshold and may trigger seizures Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.</p><p><strong>Patients with G-6- phosphate dehydrogenase deficiency</strong></p><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p><strong>Patients with renal impairment</strong></p><p>Since levofloxacin is excreted mainly by the kidneys, the dose of Levofloxacin solution for infusion should be adjusted in patients with renal impairment (see section 4.2).</p><p><strong>Hypersensitivity reactions</strong></p><p>Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><p><strong>Severe cutaneous adverse reactions</strong></p><p>Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN: also known as Lyell&#39;s syndrome), Stevens Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with levofloxacin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored. If signs and symptoms suggestive of these reactions appear, levofloxacin should be discontinued immediately and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS, TEN or DRESS with the use of levofloxacin, treatment with levofloxacin must not be restarted in this patient at any time.</p><p><strong>Dysglycaemia</strong></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p><strong>Prevention of photosensitization</strong></p><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium) during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitization.</p><p><strong>Patients treated with Vitamin K antagonists</strong></p><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomittantly (see section 4.5).</p><p><strong>Psychotic reactions</strong></p><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour - sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><strong>QT interval prolongation</strong></p><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>- congenital long QT syndrome</p><p>- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>- uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)</p><p>- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.</p><p>(See section 4.2&nbsp;Elderly, 4.5, 4.8 and 4.9).</p><p><strong>Peripheral neuropathy</strong></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with levofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8).</p><p><strong>Hepatobiliary disorders</strong></p><p>Cases of hepatic necrosis up to life threatening hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><p><strong>Exacerbation of myasthenia gravis</strong></p><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.</p><p><strong>Vision disorders</strong></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><strong>Superinfection</strong></p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><strong>Interference with laboratory test</strong></p><p>In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.</p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known atherosclerosis).</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><u>Effect of other medicinal products on levofloxacin</u></p><p><strong>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</strong></p><p>No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents, which lower the seizure threshold.</p><p>Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.</p><p><strong>Probenecid and Cimetidine</strong></p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.</p><p>Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p><strong>Other relevant information</strong></p><p>Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><p><strong>Effect of levofloxacin on other medicinal products</strong></p><p><strong>Ciclosporin</strong></p><p>The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.</p><p><strong>Vitamin K antagonists</strong></p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4)</p><p><strong>Drugs known to prolong QT interval</strong></p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).</p><p><strong>Other relevant information</strong></p><p>In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><strong>Fertility, pregnancy and lactation</strong></p><p><strong>Pregnancy</strong></p><p>There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see sections 4.3 and 5.3).</p><p><strong>Breast-feeding</strong></p><p>Levofloxacin is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk, however other fluoroquinolones are excreted in breast milk. In the absence of these data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><p><strong>Fertility</strong></p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>The information given below is based on data from clinical studies in more than 5000 patients and on extensive post marketing experience.</p><p>Frequencies in this table are defined using the following convention: very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fungal infection including Candida infection</p><p>Pathogen resistance</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood and the lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia</p><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Neutropenia</p></td><td style="vertical-align:top"><p>Pancytopenia</p><p>Agranulocytosis</p><p>Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system Disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angioedema</p><p>Hypersensitivity(see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylactic shock&nbsp;<sup>a</sup></p><p>Anaphylactoid shock&nbsp;<sup>a</sup></p><p>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Hypoglycaemia particularly in diabetic patients</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemic coma</p><p>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders*</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety</p><p>Confusional state</p><p>Nervousness</p></td><td style="vertical-align:top"><p>Psychotic reactions (with e.g. hallucination, paranoia)</p><p>Depression Agitation Abnormal dreams Nightmares</p></td><td style="vertical-align:top"><p>Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt</p><p>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system Disorders*</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Tremor</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Convulsion (see sections 4.3 and 4.4) Paraesthesia</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy (see section 4.4) Peripheral sensory motor neuropathy (see section 4.4)</p><p>Parosmia including anosmia</p><p>Dyskinesia</p><p>Extrapyramidal disorder</p><p>Ageusia</p><p>Syncope</p><p>Benign intracranial hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Visual disturbances such as blurred vision (see section 4.4)</p></td><td style="vertical-align:top"><p>Transient vision loss (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Ear and Labyrinth disorders*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Hearing loss</p><p>Hearing impaired</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia,</p><p>Palpitation</p></td><td style="vertical-align:top"><p>Ventricular tachycardia, which may result in cardiac arrest</p><p>Ventricular arrhythmia and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation),</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em><u>Applies to iv</u></em><em>&nbsp;<u>form only:</u></em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p><p>Pneumonitis allergic</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Vomiting</p><p>Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Dyspepsia Flatulence Constipation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea &ndash; haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis (see section 4.4)</p><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT)</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Jaundice and severe liver injury, including fatal cases with acute liver failure, primarily in patients with severe underlying diseases (see section 4.4)</p><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders&nbsp;<sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash<br />Pruritus<br />Urticaria<br />Hyperhidrosis</p></td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (see section 4.4), Fixed drug eruption</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome Erythema multiforme Photosensitivity reaction (see section 4.4)</p><p>Leukocytoclastic vasculitis</p><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendon disorders (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon)</p><p>Muscular</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and</p><p>4.4)</p><p>Ligament rupture Muscle rupture Arthritis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Renal failure acute (e.g. due to interstitial nephritis)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions*</p></td><td style="vertical-align:top"><p><em><u>Applies to iv</u></em><em>&nbsp;<u>form only:</u></em></p><p>Infusion site reaction (pain, reddening)</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Pain (including pain in back, chest, and extremities)</p></td></tr></tbody></table><p><em>Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose.</em></p><p><sup>b</sup>&nbsp;Mucocutaneous reactions may sometimes occur even after the first dose</p><p>*Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&bull; attacks of porphyria in patients with porphyria</p><p><strong>Note: </strong><strong>To Report any Side Effect(s):</strong></p><p>&middot;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p>- TOLL FREE : 8002490000</p><p>- E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>- Website: <u>https://ade.sfda.gov.sa/</u></p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdosage of Levofloxacin Solution for infusion are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group</u>:</p><p>Quinolone antibacterials - Fluoroquinolones</p><p>ATC Code: J01MA12</p><p>Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic drug substance ofloxacin.</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Mechanism of action </u></strong></p><p>As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>PK/PD relationship</u></strong></p><p>The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mechanism of resistance</strong></p><p>The main mechanism of resistance is due to a&nbsp;gyr-A&nbsp;mutation.&nbsp;In vitro&nbsp;there is a cross-resistance between levofloxacin and other fluoroquinolones.</p><p>Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Breakpoints</strong></p><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/L).</p><p>EUCAST clinical MIC breakpoints for levofloxacin (2009-04-07):</p><table border="1" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:top"><p>Pathogen</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Resistant</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriacae</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A,B,C,G</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>S.pneumoniae&nbsp;<sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>H.influenzae<sup>2, 3</sup></em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>M.catarrhalis<sup>3</sup></em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Non-species related breakpoints<sup>4</sup></em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1. The breakpoints for levofloxacin relate to high dose therapy.</p><p>2. Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with H. influenzae.</p><p>3.Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.</p><p>4. Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p><strong>Absorption: </strong></p><p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2h. The absolute bioavailability is 99-100 %.</p><p>Food has little effect on the absorption of levofloxacin</p><p><strong>Distribution:</strong></p><p>Approximately 30 - 40 % of levofloxacin is bound to serum protein. The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p><strong>Penetration into tissues and body fluids:</strong></p><p>Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration intro cerebro-spinal fluid.</p><p><strong>Biotransformation</strong></p><p>Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt; 5 % of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.</p><p><strong>Elimination</strong></p><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12;: 6 - 8 h). Excretion is primarily by the renal route (&gt; 85 % of the administered dose).</p><p>There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><p><strong>Linearity</strong></p><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.</p><p><strong>Special populations</strong></p><p><strong>Subjects with renal insufficiency</strong></p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td><p>Clcr&nbsp;[ml/min]</p></td><td><p>&lt; 20</p></td><td><p>20 - 49</p></td><td><p>50 - 80</p></td></tr><tr><td><p>ClR&nbsp;[ml/min]</p></td><td><p>13</p></td><td><p>26</p></td><td><p>57</p></td></tr><tr><td><p>t1/2&nbsp;[h]</p></td><td><p>35</p></td><td><p>27</p></td><td><p>9</p></td></tr></tbody></table><p><strong>Elderly subjects</strong></p><p>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</p><p><strong>Gender differences</strong></p><p>Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.</p><p>Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells&nbsp;in vitro. These effects can be attributed to inhibition of topoisomerase II.&nbsp;In vivo&nbsp;tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photo mutagenicity assay, and it reduced tumour development in a photocarcinogenity study.</p><p>In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid,&nbsp;(for pH adjustment)</p><p>Water for Injection&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levofloxacin 5 mg/ml Solution for infusion should not be mixed with heparin or alkaline solutions (e.g. sodium hydrogen carbonate). This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life as packaged for sale: 2 years.
Shelf life after removal of the outer carton/overwrap pouch – to be used immediately.
Shelf life after perforation of the rubber stopper: (see section 6.6).
From a microbiological point of view, the solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Protect from light.</p><p>Keep bottle/bag in the outer carton/over wrap pouch in order to protect from light (see section 6.3). Inspect visually prior to use. Only clear solutions without particles should be used.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bottles of low-density polyethylene; contents:, 100 ml</p><p>Pack size: 50 &times; 100 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levofloxacin Solution for infusion should be used immediately (within 3 hours) after perforation of the rubber stopper in order to prevent any bacterial contamination.</p><p>No protection from light is necessary during infusion.</p><p>For single use only. Discard any unused solution.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>Mixture with other solutions for infusion:</strong></p><p>Levofloxacin Solution for infusion is compatible with the following solutions for infusion:</p><p>0.9 % sodium chloride solution USP.</p><p>5 % dextrose injection USP.</p><p>2.5 % dextrose in Ringer solution.</p><p>Combination solutions for parenteral nutrition (amino acids, carbohydrates, electrolytes).</p><p>See section 6.2 for incompatibilities</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AlRazi Pharmaceutical Industries
2nd Industrial City, Dammam,
street 67 cross 110
Saudi Arabia2nd Industrial City, Dammam,
info@alrazi-pharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>